In ARCTIC , 2440 patients were randomized before coronary stenting to a strategy of platelet function monitoring ( VerifyNow P2Y12/aspirin point-of-care assay ) with drug adjustment in suboptimal responders to antiplatelet therapy or to a conventional strategy without monitoring and without drug or dose changes .